NDA 218590 · Knoa Pharma
Zurnai (Autoinjector)
Nalmefene Hydrochloride · Intramuscular, Subcutaneous
Priority reviewLast checked: Nov 20, 2026Latest source record: Aug 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Aug 7, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
37
9 Phase 3, 2 recruiting
FAERS reports
32
29 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 31, 2026.
ZURNAI is indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZURNAI is not a substitute for emergency medical care. ZURNAI is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. ( 1 ) ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) ZURNAI is not a substitute for emergency medical care. ( 1 )
Mechanism: ZURNAI is an antagonist at opioid receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZURNAI (AUTOINJECTOR) · NALMEFENE HYDROCHLORIDE EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML) · SOLUTION, INTRAMUSCULAR, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nalmefene" as an intervention, any sponsor and status, largest first.
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT02364947 · 678 participants · Start Feb 9, 2015 · Primary completion Jul 30, 2016
Drug: Nalmefene hydrochloride; Placebo · For: Alcohol Dependence
Sites: Region, Japan · 7 sites in all
- Efficacy of Nalmefene in Patients With Alcohol DependencePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00812461 · 678 participants · Start Mar 2009 · Primary completion Mar 2011
Drug: Placebo; Nalmefene · For: Alcohol Dependence
Sites: Assebroek, Belgium; Bruges, Belgium; Charleroi, Belgium · 57 sites in all
- Safety and Efficacy of Nalmefene in Patients With Alcohol DependencePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00811941 · 665 participants · Start Mar 2009 · Primary completion Nov 2010
Drug: Placebo; Nalmefene · For: Alcohol Dependence
Sites: Litoměřice, Czechia; Lnáře, Czechia; Prague, Czechia · 60 sites in all
- Efficacy of Nalmefene in Patients With Alcohol DependencePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00811720 · 598 participants · Start Dec 2008 · Primary completion Oct 2010
Drug: Placebo; Nalmefene · For: Alcohol Dependence
Sites: Linz, Austria; Salzburg, Austria; Vienna, Austria · 39 sites in all
- Effect of Nalmefene on the Quality of Resuscitation in Patients Under General AnesthesiaPivotal-lookingCompleted
RenJi HospitalAcademic, hospital or other
NCT04713358 · 542 participants · Start Sep 24, 2021 · Primary completion Dec 31, 2023
Drug: Nalmefene; normal Saline · For: Resuscitation
Sites: Guangxi, China; Shanghai, China; Henan, China · 4 sites in all
- A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol DependencePivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT02382276 · 405 participants · Start Jul 13, 2015 · Primary completion Jan 18, 2017
Drug: Nalmefene hydrochloride · For: Alcohol Dependence
Sites: Region, Japan · 7 sites in all
H. Lundbeck A/SIndustry
NCT02195817 · 378 participants · Start Aug 2014 · Primary completion Feb 2016
Drug: Selincro® 18 mg with continuous psychosocial support: Cohort A · For: Alcohol Dependence
Sites: Bécon-les-Granits, France; Bordeaux, France; Cestas, France · 48 sites in all
- NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural AddictionsPivotal-lookingRecruiting
Nantes University HospitalAcademic, hospital or other
NCT05540288 · 266 participants (planned) · Start Mar 31, 2023 · Primary completion Jul 2027
Drug: Nalmefene; Placebo · For: Behavioural Addiction
Sites: Besançon, France; Bordeaux, France; Brest, France · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- coma5
- bradycardia4
- bradypnoea4
- electrocardiogram qt prolonged4
- hypothermia4
- intentional overdose4
- miosis4
- diabetic ketoacidosis3
- pneumonia aspiration3
- pulmonary oedema3
- sudden death3
- bipolar i disorder2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2010 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · J Addict Med 2022 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Pharmacological management of gambling disorder: A systematic review and network meta-analysis.
Ioannidis K, Del Giovane C, Tzagarakis C, et al. · Compr Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis.
Kotake K, Hosokawa T, Tanaka M, et al. · Addiction 2024 · Systematic Review, Network Meta-Analysis
- Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
Palpacuer C, Laviolle B, Boussageon R, et al. · PLoS Med 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Can alcohol dependent patients adhere to an 'as-needed' medication regimen?
Sinclair J, Chick J, Sørensen P, et al. · Eur Addict Res 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Opioid Antagonists for Pharmacological Treatment of Gambling Disorder: Are they Relevant?
Victorri-Vigneau C, Spiers A, Caillet P, et al. · Curr Neuropharmacol 2018 · Systematic Review
Sponsor: Knoa Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.